search
Back to results

Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis

Primary Purpose

Clostridium Difficile

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Stool
Sponsored by
OSF Healthcare System
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Clostridium Difficile focused on measuring C-Diff, Diarrhea

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Patients > 18 years of age
  2. The patient has been treated with appropriate antimicrobial therapy for CDI.
  3. The patient has documented relapse/recurrence of infection as demonstrated by positive stool culture, or cytotoxin assay, or PCR toxin assay.
  4. Since this study does not involve treatments that have potential teratogenicity, and in general avoidance of antimicrobial treatment during pregnancy is advised (metronidazole is pregnancy category C), women of child-bearing age may be included in the study.

Exclusion Criteria:

- Patients will be excluded from study participation if one of the following categories of exclusion criteria applies:

  1. Patient is < 18 years of age
  2. Patient has an absolute neutrophil count < 750 cells/mm3.

Stool donors must:

  1. be > 18 years of age
  2. Complete a screening questionnaire:

    a. One-time donors: Table 1 b. Designated, pre-screened donors: Table 2

  3. Be tested for communicable blood-borne and enteric pathogens:

    1. One-time donors: Table 3
    2. Designated, pre-screened donors: Table 4

Table 1: Questionnaire to screen one-time stool donors prior to FMT.

You have been identified as a potential stool donor by __________________ , your (spouse/ son/ daughter/ mother/ father/ life partner), who has been referred for fecal transplantation. Prior to performing the transplantation procedure, the OSF/Saint Francis Medical Center Infection Control Committee requires completion of a screening questionnaire by all potential stool donors:

Your name: ___________________________________________ Date: ___/___/ 2013

Your relationship to the patient: ___________________________ YES / NO

  1. Have you ever been diagnosed with Clostridium difficile colitis?
  2. Are you currently taking antibiotic medications?
  3. Have you been prescribed antibiotics in the past six weeks?

IF the potential stool donor answers YES to questions 1, 2, or 3 - please STOP.

Do you have a history of any of the following: (Please Circle)

Hepatitis A YES / NO Hemophilia YES / NO Hemodialysis treatment YES / NO Rejected or refused blood donation YES / NO HIV/AIDS YES / NO Hepatitis B YES / NO Hepatitis C YES / NO Use of intravenous drugs or medications YES / NO Incarceration YES / NO Abnormal blood tests of liver enzymes YES / NO Accepting money or drugs in exchange for sex YES / NO Receipt of a blood transfusion between 1977 - 1992 YES / NO Infectious gastroenteritis or diarrhea YES / NO

Did you answer YES to any of the above? YES / NO

Table 2: Questionnaire to screen designated stool donors prior to each FMT.

You have been identified as a potential stool donor for a patient who has been referred to Saint Francis Medical Center for fecal transplantation. Prior to performing the transplantation procedure, the OSF/Saint Francis Medical Center Infection Control Committee requires completion of a screening questionnaire by all potential stool donors:

Your name: ___________________________________________ Date: ___/___/ 2013

Your relationship to the patient: ___________________________ YES / NO

1. Have you ever been diagnosed with Clostridium difficile colitis?

4. Are you currently taking antibiotic medications?

5. Have you been prescribed antibiotics in the past six weeks?

IF the potential stool donor answers YES to questions 1, 2, or 3 - please STOP.

Do you have a history of any of the following: (Please Circle)

Hepatitis A YES / NO Hemophilia YES / NO Hemodialysis treatment YES / NO Rejected or refused blood donation YES / NO HIV/AIDS YES / NO Hepatitis B YES / NO Hepatitis C YES / NO Use of intravenous drugs or medications YES / NO Incarceration YES / NO Abnormal blood tests of liver enzymes YES / NO Accepting money or drugs in exchange for sex YES / NO Receipt of a blood transfusion between 1977 - 1992 YES / NO Infectious gastroenteritis or diarrhea YES / NO

Did you answer YES to any of the above? YES / NO

Table 3: Required stool donor screening laboratory studies prior to FMT

Stool:

Giardia & Cryptosporidium stool antigen testing Stool ova & parasite testing Cultures for Salmonella, Shigella and E. coli O157:H7 Clostridium difficile toxin B PCR assay

Blood:

HIV 1&2 Ab/Ag HAV IgM Ab HBV core Ab & Ag HCV Ab HTLV-1 Ab

Table 4: Laboratory studies every 120 days for designated stool donors

Stool:

Giardia & Cryptosporidium stool antigen testing Stool ova & parasite testing Cultures for Salmonella, Shigella and E. coli O157:H7 Clostridium difficile toxin B PCR assay

Blood:

HIV 1&2 Ab/Ag HAV IgM Ab HBV core Ab & Ag HCV Ab HTLV-1 Ab

Sites / Locations

  • OSF Saint Francis Medical CenterRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Fecal Microbiota Therapy

Arm Description

Outcomes

Primary Outcome Measures

Weight and Number of bowel movements/day
In the present study we will record each subjects weight and number of bowel movements/day prior to FMT and following FMT at 30 and 90 days.

Secondary Outcome Measures

Evaluate the most appropriate patient population for FMT
Our study will include ambulatory outpatients as well as hospitalized, debillitated patients. FMT has demonstrated effectiveness (both systematic reviews and RCT) for treatment of recurrent Clostridium difficile infection in ambulatory outpatient populations. A secondary outcome of our study is to evaluate stratify our patient population and examine FMT success rates for out two primary outcome measures in outpatients vs. inpatients.
Determine the overall success of FMT
An additional secondary outcome measure will be to examine the percent of patients who undergo 2nd or third FMT. and the success rate (in terms of primary outcome measures) for each subsequent FMT.

Full Information

First Posted
October 21, 2013
Last Updated
October 25, 2013
Sponsor
OSF Healthcare System
search

1. Study Identification

Unique Protocol Identification Number
NCT01973465
Brief Title
Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis
Official Title
Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis
Study Type
Interventional

2. Study Status

Record Verification Date
October 2013
Overall Recruitment Status
Unknown status
Study Start Date
September 2013 (undefined)
Primary Completion Date
September 2014 (Anticipated)
Study Completion Date
September 2014 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
OSF Healthcare System

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study was developed in response to the July, 2013 FDA draft guidance regarding FMT for CDI. The weight of the evidence in the literature suggests that FMT is the most effective treatment for ambulatory outpatients affected by recurrent CDI who fail conventional therapy. The anticipated benefits to research patients enrolled in this study include resolution of chronic diarrhea, return of bowel habits and nutritional status to normal, and resolution of chronic recurrent CDI. FMT involves the endoscopic instillation of freshly obtained stool with millions of live bacteria into the recipient's colon by endoscopic lavage. With any endoscopic procedure, there is a risk of perforated viscous. This is very rare, but the risk is increased with severe CDI. The risk of acquisition of communicable enteric or blood borne pathogen appears to be negligible.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Clostridium Difficile
Keywords
C-Diff, Diarrhea

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Fecal Microbiota Therapy
Arm Type
Experimental
Intervention Type
Biological
Intervention Name(s)
Stool
Intervention Description
Implanting fecal matter via colonscope
Primary Outcome Measure Information:
Title
Weight and Number of bowel movements/day
Description
In the present study we will record each subjects weight and number of bowel movements/day prior to FMT and following FMT at 30 and 90 days.
Time Frame
30 and 90 days
Secondary Outcome Measure Information:
Title
Evaluate the most appropriate patient population for FMT
Description
Our study will include ambulatory outpatients as well as hospitalized, debillitated patients. FMT has demonstrated effectiveness (both systematic reviews and RCT) for treatment of recurrent Clostridium difficile infection in ambulatory outpatient populations. A secondary outcome of our study is to evaluate stratify our patient population and examine FMT success rates for out two primary outcome measures in outpatients vs. inpatients.
Time Frame
30 and 90 days
Title
Determine the overall success of FMT
Description
An additional secondary outcome measure will be to examine the percent of patients who undergo 2nd or third FMT. and the success rate (in terms of primary outcome measures) for each subsequent FMT.
Time Frame
30 and 90 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patients > 18 years of age The patient has been treated with appropriate antimicrobial therapy for CDI. The patient has documented relapse/recurrence of infection as demonstrated by positive stool culture, or cytotoxin assay, or PCR toxin assay. Since this study does not involve treatments that have potential teratogenicity, and in general avoidance of antimicrobial treatment during pregnancy is advised (metronidazole is pregnancy category C), women of child-bearing age may be included in the study. Exclusion Criteria: - Patients will be excluded from study participation if one of the following categories of exclusion criteria applies: Patient is < 18 years of age Patient has an absolute neutrophil count < 750 cells/mm3. Stool donors must: be > 18 years of age Complete a screening questionnaire: a. One-time donors: Table 1 b. Designated, pre-screened donors: Table 2 Be tested for communicable blood-borne and enteric pathogens: One-time donors: Table 3 Designated, pre-screened donors: Table 4 Table 1: Questionnaire to screen one-time stool donors prior to FMT. You have been identified as a potential stool donor by __________________ , your (spouse/ son/ daughter/ mother/ father/ life partner), who has been referred for fecal transplantation. Prior to performing the transplantation procedure, the OSF/Saint Francis Medical Center Infection Control Committee requires completion of a screening questionnaire by all potential stool donors: Your name: ___________________________________________ Date: ___/___/ 2013 Your relationship to the patient: ___________________________ YES / NO Have you ever been diagnosed with Clostridium difficile colitis? Are you currently taking antibiotic medications? Have you been prescribed antibiotics in the past six weeks? IF the potential stool donor answers YES to questions 1, 2, or 3 - please STOP. Do you have a history of any of the following: (Please Circle) Hepatitis A YES / NO Hemophilia YES / NO Hemodialysis treatment YES / NO Rejected or refused blood donation YES / NO HIV/AIDS YES / NO Hepatitis B YES / NO Hepatitis C YES / NO Use of intravenous drugs or medications YES / NO Incarceration YES / NO Abnormal blood tests of liver enzymes YES / NO Accepting money or drugs in exchange for sex YES / NO Receipt of a blood transfusion between 1977 - 1992 YES / NO Infectious gastroenteritis or diarrhea YES / NO Did you answer YES to any of the above? YES / NO Table 2: Questionnaire to screen designated stool donors prior to each FMT. You have been identified as a potential stool donor for a patient who has been referred to Saint Francis Medical Center for fecal transplantation. Prior to performing the transplantation procedure, the OSF/Saint Francis Medical Center Infection Control Committee requires completion of a screening questionnaire by all potential stool donors: Your name: ___________________________________________ Date: ___/___/ 2013 Your relationship to the patient: ___________________________ YES / NO 1. Have you ever been diagnosed with Clostridium difficile colitis? 4. Are you currently taking antibiotic medications? 5. Have you been prescribed antibiotics in the past six weeks? IF the potential stool donor answers YES to questions 1, 2, or 3 - please STOP. Do you have a history of any of the following: (Please Circle) Hepatitis A YES / NO Hemophilia YES / NO Hemodialysis treatment YES / NO Rejected or refused blood donation YES / NO HIV/AIDS YES / NO Hepatitis B YES / NO Hepatitis C YES / NO Use of intravenous drugs or medications YES / NO Incarceration YES / NO Abnormal blood tests of liver enzymes YES / NO Accepting money or drugs in exchange for sex YES / NO Receipt of a blood transfusion between 1977 - 1992 YES / NO Infectious gastroenteritis or diarrhea YES / NO Did you answer YES to any of the above? YES / NO Table 3: Required stool donor screening laboratory studies prior to FMT Stool: Giardia & Cryptosporidium stool antigen testing Stool ova & parasite testing Cultures for Salmonella, Shigella and E. coli O157:H7 Clostridium difficile toxin B PCR assay Blood: HIV 1&2 Ab/Ag HAV IgM Ab HBV core Ab & Ag HCV Ab HTLV-1 Ab Table 4: Laboratory studies every 120 days for designated stool donors Stool: Giardia & Cryptosporidium stool antigen testing Stool ova & parasite testing Cultures for Salmonella, Shigella and E. coli O157:H7 Clostridium difficile toxin B PCR assay Blood: HIV 1&2 Ab/Ag HAV IgM Ab HBV core Ab & Ag HCV Ab HTLV-1 Ab
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
April A Howarter, BSN
Phone
309-624-2409
Email
April.a.howarter@osfhealthcare.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
John J Farrell, M.D.
Organizational Affiliation
OSF Healthcare System
Official's Role
Principal Investigator
Facility Information:
Facility Name
OSF Saint Francis Medical Center
City
Peoria
State/Province
Illinois
ZIP/Postal Code
61637
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Citations:
Citation
Hall IC, O'Toole E. Intestinal flora in newborn infants with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child 1935;49:390-402.
Results Reference
background
PubMed Identifier
625309
Citation
Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med. 1978 Mar 9;298(10):531-4. doi: 10.1056/NEJM197803092981003.
Results Reference
background
PubMed Identifier
23323867
Citation
van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013 Jan 31;368(5):407-15. doi: 10.1056/NEJMoa1205037. Epub 2013 Jan 16.
Results Reference
background
PubMed Identifier
22002980
Citation
Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011 Nov;53(10):994-1002. doi: 10.1093/cid/cir632.
Results Reference
background
Citation
True E, Tsoraides S, Bonello JP. Fecal Microbiota Therapy in the Treatment of Clostridium difficile diarrhea. 63rd Annual Scientific Meeting, Illinois Chapter, American College of Surgeons. June 7, 2013.
Results Reference
background
Citation
Sax, PE. NEJM Journal Watch. http://blogs.jwatch.org/hiv-id-observations/index.php/fda-fecal- transplants-need-investigational-new-drug-application/2013/05/12/
Results Reference
background

Learn more about this trial

Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis

We'll reach out to this number within 24 hrs